Skip to main content
Premium Trial:

Request an Annual Quote

Promega PowerPlex Y23 System Receives NDIS Approval

NEW YORK (GenomeWeb News) – Promega said today that its PowerPlex Y23 System has been approved for use in laboratories generating DNA records for the National DNA Index System.

The NDIS, part of the Federal Bureau of Investigation's Combined DNA Index System, contains more than 10 million offender and forensic DNA profiles contributed by federal, state, and local forensic labs used to identify criminals.

The PowerPlex Y23 system is a "rapid human Y-chromosome short tandem repeat" assay for forensic applications, offender databasing, and relationship testing, Promega said. Launched in July 2012, it reduces thermal cycling time by about half, according to the company, and detects "substantially more" Y-STR loci than other systems.

The system co-amplifies 23 Y-STR loci, the Madison, Wis.-based firm added, including all Y-STR loci found in key STR databases in the US and Europe.

Previously, Promega's PowerPlex 18D system received NDIS approval in 2011, and its PowerPlex 16 HS system was approved in 2009.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.